Chemotherapy News and Research

Latest Chemotherapy News and Research

Seattle Genetics lymphoma drug gets FDA panel nod

Seattle Genetics Inc. has finally obtained the U.S. Food and Drugs Administration (FDA) nod for a second type of blood cancer drug. The FDA advisory committee voted 10-0 on Thursday to recommend accelerated approval of the drug, under the proposed trade name Adcetris, for anaplastic large cell lymphoma (ALCL). The panel earlier unanimously approved the drug for Hodgkin's lymphoma, another type of blood cancer.

14 Jul 2011

Scientists discover new mechanism of drug resistance in hospital microbes

Hospitals struggle to prevent the infections that complicate treatment for cancer, joint replacement, heart surgery and other conditions. Hospital-acquired infections are often resistant to multiple antibiotics, leading to approximately 100,000 deaths and more than $30 billion in additional health care costs yearly.

14 Jul 2011

Progesterone could fight against neuroblastoma

High doses of the hormone progesterone can kill neuroblastoma cells while leaving healthy cells unscathed, scientists at Emory University School of Medicine have found in laboratory research.

14 Jul 2011

ASLAN, Array sign license agreement to develop ARRY-543 for solid tumors

ASLAN Pharmaceuticals Pte Ltd and Array BioPharma Inc. today announced a license agreement to develop Array's HER2 / EGFR inhibitor, ARRY-543, currently entering Phase 2 development for solid tumors.

14 Jul 2011

U.S. Senators introduce Pulmonary Fibrosis Research Enhancement Act

The Coalition for Pulmonary Fibrosis (CPF) announced today the Pulmonary Fibrosis Research Enhancement Act has been introduced in the Senate by Senators Chris Coons and Mike Crapo in the U.S. House of Representatives by Rep. Erik Paulsen and Rep. Tammy Baldwin.

13 Jul 2011

U.S. hospitals report severe drug shortages: Survey

A survey called “Impact of Drug Shortages on U.S. Health Systems” released this Tuesday showed that a vast majority of U.S. hospitals have restricted the use of life-saving chemotherapy drugs and other critical-care medications in the past six months to cope with unprecedented shortages.

13 Jul 2011

Blood cancer drug trial results questioned by FDA

U.S. drug reviewers might limit the use of a Seattle Genetics Inc’s experimental blood cancer drug due to the narrow scope of its clinical trials. According to papers released Tuesday by the Food and Drug Administration (FDA), it requests an advisory panel to consider the drug, under the proposed trade name Adcetris known chemically as brentuximab vedotin, for use in previously treated patients with Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL).

13 Jul 2011

New insights into how cancer cells can maintain resistance to chemotherapy

Researchers from the Royal College of Surgeons in Ireland (RCSI) have conducted a study which reveals new insights into how cancer cells can maintain a resistance to chemotherapy resulting in cancer relapse.

12 Jul 2011

New method allows for concurrent treatment of spinal tumors and stabilization of the spine

The Orthopedic Clinic and Policlinic at the University Medical Center of Johannes Gutenberg University Mainz has recently deployed a new system for the treatment of spinal tumors for the first time.

11 Jul 2011

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland, announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.

11 Jul 2011

New radiofrequency ablation system for treating spinal tumors

The Orthopedic Clinic and Policlinic at the University Medical Center of Johannes Gutenberg University Mainz (JGU) has recently deployed a new system for the treatment of spinal tumors for the first time.

11 Jul 2011

Nature journal publishes landmark genetic study of ovarian cancer

A University of Houston researcher is an author on a landmark multi-institutional genetic study of the most aggressive and common form of ovarian cancer that is published in the current issue of the scientific journal Nature.

11 Jul 2011

Combination therapy shows promise against HER2-positive metastatic breast cancer

Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the Journal of Clinical Oncology.

11 Jul 2011

Patients with high-grade noninvasive bladder cancer do not receive recommended care

A new study has found that almost all patients with high-grade noninvasive bladder cancer do not receive complete care as recommended by current guidelines.

11 Jul 2011

Research targets malignant glioma stem cells

Cleveland Clinic researchers have identified a cellular pathway that cancer stem cells use to promote tumor growth in malignant glioma, an aggressive brain tumor.

11 Jul 2011

Charité-Universitätsmedizin Berlin establishes MagForce NanoTherm therapy center for treatment of tumors

Nanostart subsidiary MagForce Nanotechnologies AG, a leading medical technology company focusing on nanomedicine in oncology, announced that the Charité-Universitätsmedizin Berlin published the establishment of its NanoTherm therapy center for the treatment of recurrent brain tumors.

8 Jul 2011

First dog enters ADXS-HER2 dose-ranging study in canine osteosarcoma

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announces that the first dog has entered a dose-ranging in canine osteosarcoma at the University of Pennsylvania School of Veterinary Medicine.

8 Jul 2011

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy.

8 Jul 2011

Half-matched transplants widen donor pool for leukemia and lymphoma

7 Jul 2011

Study finds link between genetic variation and cetuximab rectal cancer therapy

team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can be cured by certain chemotherapies when combined with surgery.

7 Jul 2011